NCT01582815View on ClinicalTrials.gov

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Major Depressive Disorder
Interventions
DRUG

JNJ-40411813

Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.

DRUG

Placebo

Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.

Trial Locations (26)

Unknown

Burgas

Kazanlak

Rousse

Sofia

Varna

Baja

Budapest

Gyõr

Kalocsa

Chisinau

Arad

Iași

Nizny Novgorod

Saint Petersburg

Saratov

St-Peterburg

Tomsk

Donetsk

Hlevakha

Kharkiv

Kiev

Lviv

Odesa

Smila

Uzhhorod

Village Stepanovka Kherson

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01582815 - A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms | Biotech Hunter | Biotech Hunter